View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in ...

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided a clinical update on its ongoing Phase 2 study of NGC-Cap...

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • Herman Caspersen
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Stian Wibstad
 PRESS RELEASE

Transocean Ltd. Announces $130 Million Award for Ultra-Deepwater Drill...

Transocean Ltd. Announces $130 Million Award for Ultra-Deepwater Drillship STEINHAUSEN, Switzerland, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced the execution of a six-well contract in Australia with an undisclosed operator for the Deepwater Skyros. The estimated 320-day campaign is expected to commence in the first quarter of 2027 and contribute approximately $130 million in backlog, excluding compensation for mobilization and demobilization. The award includes priced options that, if fully exercised, could keep the drillship working in Au...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Transocean Ltd: 2 directors

Two Directors at Transocean Ltd sold 530,000 shares at between 4.290USD and 4.320USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
 PRESS RELEASE

MacroGenics to Participate in the 8th Annual Evercore Healthcare Confe...

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section ...

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
 PRESS RELEASE

Transocean Ltd. Announces Exercised Options Totaling $89 Million

Transocean Ltd. Announces Exercised Options Totaling $89 Million STEINHAUSEN, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) today announced contract fixtures for one ultra-deepwater drillship and two harsh environment semisubmersibles. In aggregate, the fixtures represent approximately $89 million in firm contract backlog. In Brazil, Petrobras exercised a 90-day option for the Deepwater Mykonos in direct continuation of its current program. The program is expected to contribute approximately $33 million in backlog. In Norway, a two-well option was exercised ...

 PRESS RELEASE

MacroGenics Reports Third Quarter 2025 Financial Results and Provides ...

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on ...

 PRESS RELEASE

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

MacroGenics to Participate in the Stifel 2025 Healthcare Conference ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of Mac...

 PRESS RELEASE

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Pha...

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Njål Kleiven
  • Stian Wibstad
 PRESS RELEASE

Transocean Ltd. Reports Third Quarter 2025 Results

Transocean Ltd. Reports Third Quarter 2025 Results                      Three months ended Three months ended September 30, June 30, sequential September 30, year-over-year 2025 2025 change 2024 change(In millions, except per share amounts, percentages and backlog)                   Contract drilling revenues$1,028   $988   $40   $948   $80  Revenue efficiency(1) 97.5 %  96.6 %      94.5 %    Operating and maintenance expense$584   $599   $15   $563   $(21) Net loss attributable to controlling interest$(1,923)  $(938)  $(985)  $(494)  $(1,429) Basic loss per share$(2.00)  $(1.06)  $(0.94)  ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch